Benuvia operations, llc and chromocell therapeutics corp. announce strategic partnership to advance healthcare solutions

Austin. texas, feb. 27, 2024 (globe newswire) -- benuvia operations, llc (“benuvia”), a leader in pharmaceutical innovation, and chromocell therapeutics corp. (“chromocell”), (nyse american: chro), a pioneer in the development of non-opioid pain treatment therapeutics, are pleased to announce chromocell's first development and license agreement (“agreement”). under the agreement, chromocell licensed sublingual formulation of a diclofenac spray for the treatment of acute pain, a rizatriptan intranasal spray formulation and an ondansetron sublingual spray formulation, diversifying our pipeline of non-opioid pain treatment therapies, while adding therapeutic options for related conditions. this collaboration leverages the unique strengths of both organizations to enhance patient outcomes and address unmet medical needs.
CHRO Ratings Summary
CHRO Quant Ranking